The effect of levodopa on stroke

The comparision between levodopa effect and placebo on the improvement of motor function in the patients with stroke in MCA(Middle cerebral artery),randomized.double blind study.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014042017360N1

Enrollment

114

Registered

2014-10-03

Start date

2013-04-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke. Middle cerebral artery syndrome (I66.0+)

Interventions

Intervention 1: Intervention group: levodopa-c tablet 1oo/25 mg daily for 21 days in the patients with ischemic stroke in MCA territory. Intervention 2: Control group: placebo tablet 125mr daily for 2

Treatment - Drugs

Placebo

Intervention group: levodopa-c tablet 1oo/25 mg daily for 21 days in the patients with ischemic stroke in MCA territory.

Control group: placebo tablet 125mr daily for 21 days,in the patients with ischemic stroke in MCA territory.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: the patients with ischemic strroke in the MCA territory. Exclusion criteria: 1.major depression, 2.cardiovascular disease 3.tricyclic therapy 4.SSRI therapy 5.dementia.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Motor function. Timepoint: three weeks after treatment. Method of measurement: Rivermead mobility index and Barthel index.;Language recovery. Timepoint: 4 weeks after treatment. Method of measurement: NIHSSS?.;Comparision between motor recovery of upper and lower limbs. Timepoint: 3 weeks after treatment. Method of measurement: Rivermead mobility index and Barthel index.	—

Secondary

Measure	Time frame
Spastisity. Timepoint: 3 months after treatment. Method of measurement: Ashworth modified scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Alireza Hasanzade

Ahvaz Jondishapour University of Medical Sciences

hassanzadehar@gmail.com+98 61 1374 3012

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026